MedTrace Logo

A Study of Nivolumab in Selected Uterine Cancer Patients

NCT03241745 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2024-12-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer. The investigators also want to find out what effects, good or bad, nivolumab has on the patient and their cancer.

Conditions

  • Uterine Cancer
  • Endometrial Carcinoma
  • Carcinosarcoma
  • Leiomyosarcoma
  • Undifferentiated Sarcoma
  • High Grade Endometrial Stromal Sarcoma
  • Clear Cell Carcinoma

Interventions

DRUG

Nivolumab

Nivolumab 480 mg IV once every 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Claire Friedman, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-03
Primary Completion
2024-04-01
Completion
2024-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03241745 on ClinicalTrials.gov